sodium polystyrene sulfonate powder, for suspension
alexso, inc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate is indicated for the treatment of hyperkalemia. limitation of use: sodium polystyrene sulfonate should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology ( 12.2 )] . sodium polystyrene sulfonate is contraindicated in patients with the following conditions: - hypersensitivity to polystyrene sulfonate resins - obstructive bowel disease - neonates with reduced gut motility risk summary sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfonate is expected to bind potassium at the practical exchange ratio of 1meq
vayego
bayer new zealand limited - tetraniliprole - suspension concentrate - tetraniliprole 200 g/litre - insecticide - insecticide
university medical pharmaceuticals antibacterial hand wash- chloroxylenol soap
university medical pharmaceuticals corp. - chloroxylenol (unii: 0f32u78v2q) (chloroxylenol - unii:0f32u78v2q) - antibacterial hand soap uses • handwash to help decrease bacteria on the skin • recommended for repeated use
university medical pharmaceuticals antibacterial hand wash- chloroxylenol soap
university medical pharmaceuticals corp. - chloroxylenol (unii: 0f32u78v2q) (chloroxylenol - unii:0f32u78v2q) - antibacterial hand soap uses • handwash to help decrease bacteria on the skin • recommended for repeated use when using this product do not use in or near the eyes. in case of contact rinse eyes thoroughly with water. stop use and ask a doctor if irritation or rash appears & lasts keep out of reach of children. if swallowed get medical help or contact a poison control center right away.
sodium polystyrene sulfonate powder, for suspension
bryant ranch prepack - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate is indicated for the treatment of hyperkalemia. limitation of use: sodium polystyrene sulfonate should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2)] . sodium polystyrene sulfonate is contraindicated in patients with the following conditions: - hypersensitivity to polystyrene sulfonate resins - obstructive bowel disease - neonates with reduced gut motility risk summary sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfonate is expected to bind potassium at the practical exchange ratio of 1meq po
sodium polystyrene sulfonate powder, for suspension
bryant ranch prepack - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. limitation of use : sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2) ] sodium polystyrene sulfonate is contraindicated in patients with the following conditions: - hypersensitivity to polystyrene sulfonate resins - obstructive bowel disease - neonates with reduced gut motility risk summary sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfonate is expected to bind potassium at the pract
sodium polystyrene sulfonate powder, for suspension
bryant ranch prepack - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. limitation of use : sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2) ] sodium polystyrene sulfonate is contraindicated in patients with the following conditions: - hypersensitivity to polystyrene sulfonate resins - obstructive bowel disease - neonates with reduced gut motility risk summary sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfonate is expected to bind potassium at the pract
sodium polystyrene sulfonate powder, for suspension
bryant ranch prepack - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. limitation of use : sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see clinical pharmacology (12.2) ] sodium polystyrene sulfonate is contraindicated in patients with the following conditions: - hypersensitivity to polystyrene sulfonate resins - obstructive bowel disease - neonates with reduced gut motility risk summary sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk. risk summary sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant. studies of safety and efficacy have not been conducted in pediatric patients. in pediatric patients, as in adults, sodium polystyrene sulfonate is expected to bind potassium at the practical exchange ratio of 1meq potassium per 1 gram of resin. in neonates, sodium polystyrene sulfonate should not be given by the oral route. in both children and neonates, excessive dosage or inadequate dilution could result in impaction of the resin. premature infants or low birth weight infants may have an increased risk for gastrointestinal adverse effects with sodium polystyrene sulfonate use [see warnings and precautions (5.4) ].